The Only Negotiation that Matters?
This article was originally published in RPM Report
Executive Summary
Economists looking at drug prices under Medicare agree on one thing: without control over formularies HHS won't have the power to drive discounts. One told Congress that instead of giving HHS more power, you should give plans full discretion to set formularies, even in the so-called protected classes. But don't count on that happening any time soon.
You may also be interested in...
Putting the Bully in the Bully Pulpit: The Democrats' Plan to Cut Drug Prices
Legislation to force price negotiation under Medicare Part D is likely to end in a stalemate. But manufacturers can't afford to relax: the Democrats plan to turn up the pressure even if a law never passes. First they will compare Part D prices to other benchmarks. Then the bullying begins.
Putting the Bully in the Bully Pulpit: The Democrats' Plan to Cut Drug Prices
Legislation to force price negotiation under Medicare Part D is likely to end in a stalemate. But manufacturers can't afford to relax: the Democrats plan to turn up the pressure even if a law never passes. First they will compare Part D prices to other benchmarks. Then the bullying begins.
Competing Priorities: Alzheimer's Drugs and the Delicate Balance that Defines Part D
The Alzheimer’s Association waged and won a six-month battle to end prior authorization programs for AD medications in three Medicare plans. The skirmish has big implications for future of Medicare formularies— and the balance of power between Big Pharma and managed care.